AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Cougar Biotechnology presents positive CB7630 Phase I data at the AACR Innovations in Prostate Cancer Research Conference.
(From Chemical Business NewsBase - Press Release)
Cougar Biotechnology Inc announced positive Phase I data on the company's prostate cancer drug candidate CB7630 (abiraterone acetate). The data was presented during the poster session at the American Association for Cancer Research (AACR) Innovations in Prostate Cancer Research Conference that is currently taking place between 6 and 9 Dec 2006 in San Francisco, CA. The Phase I trial of CB7630 was conducted at The Institute of Cancer Research and at The Royal Marsden NHS Foundation Trust in the UK. In the trial, CB7630 was administered once daily to chemotherapy-naive patients with castration refractory prostate …
-
- Investing in the Future of Prostate Cancer Research
-
News wire article from: The America's Intelligence Wire
July 31, 2012
700+ words
-
- National Foundation for Cancer Research and The Prostate Cancer Foundation...
-
News wire article from: Europe Intelligence Wire
August 25, 2005
700+ words
-
- Independent Nurse: Impotence link to prostate cancer.(research of prostate...
-
Magazine article from: GP
August 4, 2006
700+ words
-
- Prostate Cancer Research Cash Aid
-
News wire article from: Europe Intelligence Wire
February 23, 2013
700+ words
-
- Proveri Inc announces publication in 'Cancer Research' of study results with...
-
News wire article from: Chemical Business Newsbase
April 7, 2011
700+ words
